In 2006, Merck KGAA knew it badly needed to boost its specialty pharmaceutical business, which relied heavily on partial rights to one potential blockbuster oncology asset, Erbitux (cetuximab).
Researchers and drug developers have made plenty of headway fighting multiple sclerosis since the first interferon drugs became available in the 1990s. The field hit a new milestone recently with oral
Pharmaceuticals Alnara Pharmaceuticals Inc. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics Inc. Alnara secures exclusive global license to CFFT's liprotamase March — Alnara Pharma